Exon 45 skipping and dystrophin production with ENTR-601-45 in preclinical models of Duchenne muscular dystrophy

被引：0

作者：

Girgenrath, M. ^{[1
]}

Estrella, N. ^{[1
]}

Kumar, A. ^{[1
]}

Hicks, A. ^{[1
]}

Brennan, C. ^{[1
]}

Blake, S. ^{[1
]}

Li, X. ^{[1
]}

Pathak, A. ^{[1
]}

Kheirabadi, M. ^{[1
]}

Dougherty, P. ^{[1
]}

Lian, W. ^{[1
]}

Liu, N. ^{[1
]}

Gao, N. ^{[1
]}

Wang, D. ^{[1
]}

Streeter, M. ^{[1
]}

Stadheim, A. ^{[1
]}

Dhanabal, M. ^{[1
]}

Qian, Z. ^{[1
]}

机构：

[1] Entrada Therapeut, Boston, MA USA

来源：

NEUROMUSCULAR DISORDERS | 2024年 / 43卷

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

431P

引用

页数：2

共 50 条

[31] Intravenous infusion of an antisense oligonucleotide results in exon skipping in muscle dystrophin mRNA of Duchenne muscular dystrophy
Takeshima, Y
Yagi, M
Wada, H
Ishibashi, K
Nishiyama, A
Kakumoto, M
Sakaeda, T
Saura, R
Okumura, K
Matsuo, M
PEDIATRIC RESEARCH, 2006, 59 (05) : 690 - 694
[32] Intravenous Infusion of an Antisense Oligonucleotide Results in Exon Skipping in Muscle Dystrophin mRNA of Duchenne Muscular Dystrophy
Yasuhiro Takeshima
Mariko Yagi
Hiroko Wada
Kazuto Ishibashi
Atsushi Nishiyama
Mikio Kakumoto
Toshiyuki Sakaeda
Ryuichi Saura
Katsuhiko Okumura
Masafumi Matsuo
Pediatric Research, 2006, 59 : 690 - 694
[33] Eteplirsen treatment for Duchenne muscular dystrophy: Exon skipping and dystrophin production (vol 90, pg e2146, 2018)
Charleston, J. S.
NEUROLOGY, 2018, 91 (13) : 637 - 637
[34] Less is more: therapeutic exon skipping for Duchenne muscular dystrophy
Aartsma-Rus, Annemieke
van Ommen, Gert-Jan B.
LANCET NEUROLOGY, 2009, 8 (10): : 873 - 875
[35] Casimersen in Patients with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping: Interim Results from the Phase 3 ESSENCE Trial
Iannaccone, S.
Phan, H.
Straub, V
Muntoni, F.
Wolf, D.
Malhotra, J.
Chu, R.
Darton, E.
Brandl, K.
Mercuri, E.
ANNALS OF NEUROLOGY, 2022, 92 : S152 - S152
[36] Casimersen in Patients with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping: Interim Results from the Phase 3 ESSENCE Trial
Iannoccone, S.
Phan, H.
Straub, V
Muntoni, F.
Koenig, E.
Malhotra, J.
Darton, E.
Han, B.
Mercuri, E.
ANNALS OF NEUROLOGY, 2021, 90 : S155 - S155
[37] Casimersen in patients with Duchenne muscular dystrophy amenable to exon 45 skipping: Interim results from the Phase 3 ESSENCE trial
Iannaccone, S.
Phan, H.
Straub, V.
Muntoni, F.
Wolf, D.
Malhotra, J.
Chu, R.
Darton, E.
Mercuri, E.
NEUROMUSCULAR DISORDERS, 2022, 32 : S102 - S102
[38] Casimersen in patients with Duchenne muscular dystrophy amenable to exon 45 skipping: interim results from the Phase 3 ESSENCE trial
Iannaccone, S.
Phan, H.
Straub, V.
Muntoni, F.
Koenig, E.
Malhotra, J.
Han, B.
Darton, E.
Mercuri, E.
NEUROMUSCULAR DISORDERS, 2021, 31 : S94 - S95
[39] Current Outline of Exon Skipping Trials in Duchenne Muscular Dystrophy
Eser, Gokce
Topaloglu, Haluk
GENES, 2022, 13 (07)
[40] EXON SKIPPING AND DUCHENNE MUSCULAR DYSTROPHY: A CLINICAL TRIAL UPDATE
Wilton, Steve
Fletcher, Sue
JOURNAL OF GENE MEDICINE, 2013, 15 (8-9): : 330 - 330

← 1 2 3 4 5 →